Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCA · Real-Time Price · USD
0.5500
+0.0437 (8.63%)
At close: May 13, 2025, 4:00 PM
0.5323
-0.0177 (-3.22%)
Pre-market: May 14, 2025, 8:13 AM EDT
Verrica Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 29.6 | 46.33 | 69.55 | 34.27 | 15.75 | 10.69 | Upgrade
|
| Short-Term Investments | - | - | - | - | 54.6 | 54.78 | Upgrade
|
| Cash & Short-Term Investments | 29.6 | 46.33 | 69.55 | 34.27 | 70.35 | 65.47 | Upgrade
|
| Cash Growth | -39.53% | -33.38% | 102.92% | -51.29% | 7.46% | 5.57% | Upgrade
|
| Receivables | 5.65 | 0.08 | 4.42 | 0.49 | - | - | Upgrade
|
| Inventory | 2.46 | 2.46 | 1.02 | - | - | - | Upgrade
|
| Prepaid Expenses | 1.77 | 2.31 | 2.55 | 4.36 | 3.97 | 2.18 | Upgrade
|
| Total Current Assets | 39.47 | 51.18 | 77.53 | 39.12 | 74.33 | 67.65 | Upgrade
|
| Property, Plant & Equipment | 2.33 | 2.58 | 3.62 | 5.33 | 5.5 | 4.94 | Upgrade
|
| Long-Term Deferred Charges | - | - | - | - | - | 0.1 | Upgrade
|
| Other Long-Term Assets | 0.38 | 0.38 | 0.45 | 0.28 | 0.3 | 1.47 | Upgrade
|
| Total Assets | 42.18 | 54.13 | 81.6 | 44.72 | 80.13 | 74.15 | Upgrade
|
| Accounts Payable | 1.44 | 1.9 | 2.46 | 0.51 | 0.85 | 0.35 | Upgrade
|
| Accrued Expenses | 14.48 | 3.09 | 8.17 | 2.43 | 3.01 | 2.84 | Upgrade
|
| Short-Term Debt | - | - | - | - | 41.69 | 35.32 | Upgrade
|
| Current Portion of Long-Term Debt | 12.82 | 12.94 | - | - | - | - | Upgrade
|
| Current Portion of Leases | 0.65 | 0.67 | 0.7 | 0.3 | 0.25 | 0.2 | Upgrade
|
| Current Unearned Revenue | - | - | - | - | - | 0.5 | Upgrade
|
| Other Current Liabilities | - | 10.42 | 5.69 | 0.22 | 0.26 | 0.28 | Upgrade
|
| Total Current Liabilities | 29.4 | 29.01 | 17.02 | 3.46 | 46.06 | 39.48 | Upgrade
|
| Long-Term Debt | 27.81 | 30.98 | 42.87 | - | - | - | Upgrade
|
| Long-Term Leases | 1.16 | 1.35 | 1.94 | 1.23 | 1.47 | 1.69 | Upgrade
|
| Other Long-Term Liabilities | 2.39 | 2.65 | - | - | - | - | Upgrade
|
| Total Liabilities | 60.75 | 63.99 | 61.83 | 4.69 | 47.52 | 41.17 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0 | 0 | 0 | 0 | Upgrade
|
| Additional Paid-In Capital | 298.18 | 297.16 | 250.21 | 203.48 | 171.6 | 136.87 | Upgrade
|
| Retained Earnings | -316.77 | -307.03 | -230.45 | -163.45 | -138.97 | -103.89 | Upgrade
|
| Comprehensive Income & Other | - | - | - | - | -0.03 | 0 | Upgrade
|
| Total Common Equity | -18.58 | -9.86 | 19.76 | 40.03 | 32.61 | 32.99 | Upgrade
|
| Shareholders' Equity | -18.58 | -9.86 | 19.76 | 40.03 | 32.61 | 32.99 | Upgrade
|
| Total Liabilities & Equity | 42.18 | 54.13 | 81.6 | 44.72 | 80.13 | 74.15 | Upgrade
|
| Total Debt | 42.43 | 45.94 | 45.51 | 1.53 | 43.41 | 37.21 | Upgrade
|
| Net Cash (Debt) | -12.84 | 0.39 | 24.04 | 32.75 | 26.95 | 28.26 | Upgrade
|
| Net Cash Growth | - | -98.38% | -26.60% | 21.53% | -4.67% | -54.29% | Upgrade
|
| Net Cash Per Share | -0.20 | 0.01 | 0.53 | 0.96 | 1.00 | 1.13 | Upgrade
|
| Filing Date Shares Outstanding | 91.79 | 91.78 | 42.42 | 41.85 | 27.52 | 25.44 | Upgrade
|
| Total Common Shares Outstanding | 91.79 | 91.78 | 42.41 | 41.09 | 27.52 | 25.44 | Upgrade
|
| Working Capital | 10.08 | 22.17 | 60.51 | 35.66 | 28.27 | 28.18 | Upgrade
|
| Book Value Per Share | -0.20 | -0.11 | 0.47 | 0.97 | 1.18 | 1.30 | Upgrade
|
| Tangible Book Value | -18.58 | -9.86 | 19.76 | 40.03 | 32.61 | 32.99 | Upgrade
|
| Tangible Book Value Per Share | -0.20 | -0.11 | 0.47 | 0.97 | 1.18 | 1.30 | Upgrade
|
| Machinery | - | 1.79 | 2.17 | 2 | 1.37 | 0.27 | Upgrade
|
| Construction In Progress | - | - | - | 2.54 | 2.73 | 2.86 | Upgrade
|
| Leasehold Improvements | - | 0.05 | 0.05 | 0.05 | 0.05 | 0.1 | Upgrade
|
Updated May 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.